Business

MARKET MOVERS

Dendreon expects slowdown in sales

istockphoto.com

Dendreon makes Provenge, which is designed to induce an immune response against prostate cancer.

Advertisement

Dendreon Corp. expects first-quarter sales to be slower than in the fourth quarter, when sales of its prostate cancer treatment Provenge were $77 million. The Seattle drug maker said first-quarter revenue growth for the drug would be in the low single digits. Fourth-quarter net income was $38.1 million, or 26 cents a share. Profit excluding some items was 45 cents a share. Analysts expected 60 cents.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.